Skip to main content

Latest news


Catch up with the latest research news, approvals, and guideline updates in oncology.


Breast cancer news

23-03-2023 | Breast cancer | News

Progestagen-only contraceptives linked to ‘slight’ increase in breast cancer risk

The current or recent use of progestagen-only contraceptives is associated with an increased risk for developing breast cancer, irrespective of the mode of delivery, suggests research published in PLOS Medicine.

More breast cancer news

17-02-2023 | Breast cancer | News

T-VEC warrants further investigation as neoadjuvant add-on in TNBC

The addition of the oncolytic virus talimogene laherparepvec to neoadjuvant chemotherapy may increase responses in women with nonmetastatic triple-negative breast cancer, say phase 2 trial investigators.

06-02-2023 | Breast cancer | News

Disparities exist in care of breast cancer patients from minority sexual orientation, gender groups

US research points to disparities in the diagnosis, treatment, and outcomes of breast cancer in people belonging to minority groups with respect to sexual orientation and gender identity.

01-02-2023 | FDA | News

FDA approves elacestrant, adds indication for pembrolizumab

Details of these breast and lung cancer decisions available here

20-01-2023 | Immunotherapy | News

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

Genitourinary cancers news

29-03-2023 | Prostate cancer | News

ProtecT 15-year results: Prostate cancer-specific mortality ‘low’ irrespective of treatment

The 15-year data from the ProtecT trial show low rates of prostate cancer-specific mortality among men with prostate-specific antigen-detected, localized disease regardless of whether they received active monitoring, prostatectomy, or radiotherapy.

08-03-2023 | EMA | News

EMA backs niraparib–abiraterone dual-action tablet for mCRPC

Read more about this decision here

More genitourinary cancers news

24-02-2023 | Renal cell carcinoma | News

CheckMate 914: Adjuvant nivolumab–ipilimumab not supported for high-risk RCC

Patients with localized renal cell carcinoma at high risk for recurrence do not derive a significant disease-free survival benefit from the postoperative use of nivolumab plus ipilimumab versus placebo, shows the phase 3 CheckMate 914 study.

Senior man holding bottle with pills and taking medicine with glass of water

14-02-2023 | Prostate cancer | News

Maintenance darolutamide shows promise in metastatic CRPC

Phase 2 data point to the potential of switch maintenance with darolutamide in men with metastatic castration-resistant prostate cancer that has not progressed after taxane therapy.

30-01-2023 | EMA | News

EMA recommends new indication for darolutamide

Click through to find out more

20-01-2023 | Immunotherapy | News

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

Lung & thoracic cancers news

14-03-2023 | EMA | News

EMA recommends extension to cemiplimab indication

Click through for more information about this lung cancer recommendation

09-02-2023 | Non-small-cell lung cancer | News

Real-world data show ‘modest’ survival gains with immunotherapy in older NSCLC patients

The overall survival benefit offered by immune checkpoint inhibitors in people with advanced non-small-cell lung cancer varies by age, suggests a real-world study.

More lung & thoracic cancers news

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox


The Medicine Matters news service is brought to you in partnership with medwireNews